2023
DOI: 10.1007/s00213-023-06313-x
|View full text |Cite
|
Sign up to set email alerts
|

Involvement of the serotonergic system in the antidepressant-like effect of 1-(phenylselanyl)-2-(p-tolyl)indolizine in mice

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
7

Relationship

2
5

Authors

Journals

citations
Cited by 8 publications
(2 citation statements)
references
References 77 publications
0
2
0
Order By: Relevance
“…Over the last decade, there has been a rapid increase in CADD-based studies of depression, including docking studies of ligands for serotonin reuptake [171,172], MAO A and MAO B [173,174], dual action on MAO-B/AChE [175], glycogen synthase kinase [176], sodium hNaV1.2 or hNaV1.7 channels [177], serotonin receptors (5HT1A, 5-HT2A, 5-HT2C and 5-HT4) [171,[178][179][180][181], adenosine A1/A2A receptors [182], T-type calcium channels [183], tryptophan 2,3-dioxygenase [184] and sigma receptor [185]. Similarly, application of docking in psychoses involved ligands for serotonin 5HT2 and dopamine D2 receptors [186], α4β2 and α7 nicotinic acetylcholine receptors [187,188], phosphodiesterase 10A [189], MAO A and B [190], a syntaxin-binding protein (STXBP1) [191], NMDA type subunit 1 (GRIN1) [192], fatty acid binding protein 7 (FABP7) [193,194], metabotropic glutamate mGluR5 receptor [195], ionotropic GABA-A receptor [196], glycine transporter type 1 (GlyT1) [197] and kynurenine aminotransferase II (KATII) [198].…”
Section: In Silico-driven Search For Novel Therapeutic Agentsmentioning
confidence: 99%
“…Over the last decade, there has been a rapid increase in CADD-based studies of depression, including docking studies of ligands for serotonin reuptake [171,172], MAO A and MAO B [173,174], dual action on MAO-B/AChE [175], glycogen synthase kinase [176], sodium hNaV1.2 or hNaV1.7 channels [177], serotonin receptors (5HT1A, 5-HT2A, 5-HT2C and 5-HT4) [171,[178][179][180][181], adenosine A1/A2A receptors [182], T-type calcium channels [183], tryptophan 2,3-dioxygenase [184] and sigma receptor [185]. Similarly, application of docking in psychoses involved ligands for serotonin 5HT2 and dopamine D2 receptors [186], α4β2 and α7 nicotinic acetylcholine receptors [187,188], phosphodiesterase 10A [189], MAO A and B [190], a syntaxin-binding protein (STXBP1) [191], NMDA type subunit 1 (GRIN1) [192], fatty acid binding protein 7 (FABP7) [193,194], metabotropic glutamate mGluR5 receptor [195], ionotropic GABA-A receptor [196], glycine transporter type 1 (GlyT1) [197] and kynurenine aminotransferase II (KATII) [198].…”
Section: In Silico-driven Search For Novel Therapeutic Agentsmentioning
confidence: 99%
“…N -(3-(Phenylselanyl)­prop-2-yn-1-yl)­benzamide (SePB, Figure ) is a synthetic organic compound containing a selenium atom and a benzamide nucleus. Synthetic organic selenium compounds have been recognized for their pharmacological properties, including their antioxidant and analgesic effects. Notably, some of these compounds have demonstrated antidepressant effects in preclinical trials. At the same time, compounds containing a benzamide nucleus have antioxidant characteristics and anti-inflammatory, analgesic, and antidepressant properties. The bond between the selenium atom and benzamide nucleus in the chemical structure of SePB has shown promising results in preclinical contexts, demonstrating a rapid antidepressant-like effect in male and female mice, with the participation of the serotonergic system through the 5-HT 1A , 5-HT 2 A /2C , 5-HT 3 , and 5-HT 4 receptors. , …”
Section: Introductionmentioning
confidence: 99%